ENB Therapeutics
  • Home
  • About
  • Pipeline
  • News/Blog
  • Contact Us
Select Page

ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023

by admin | Nov 9, 2023 | Press Releases

ENB-003 in combination with KEYTRUDA® (pembrolizumab) demonstrated encouraging objective responses, disease control and progression-free survival in patients with metastatic platinum refractory/resistant ovarian cancer (PROC) Encouraging results support further...

ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Solid Tumors Refractory to Standard of Care at the Immuno-oncology Summit 2023

by admin | Jul 21, 2023 | Press Releases

ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor – a novel immune checkpoint The ENB-003 in combination with KEYTRUDA® (pembrolizumab) was well tolerated Promising preliminary efficacy signals with 33% disease...

ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy

by admin | Nov 9, 2022 | Press Releases

Friday, November 4, 2022 7:00 AM ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor – a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / November 4, 2022 / ENB Therapeutics, Inc., a biotechnology company...

ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer

by admin | May 25, 2022 | Press Releases

Tuesday, May 24, 2022 8:00 AM https://www.accesswire.com/viewarticle.aspx?id=702335 ENB-003 is a first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / May 24, 2022 / ENB...

ENB Therapeutics Demonstrated Early Efficacy in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab

by admin | Feb 8, 2021 | Press Releases

Monday, February 1, 2021 8:00 AM https://www.accesswire.com/viewarticle.aspx?id=626781 ENB-003 is the Company’s first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint  NEW YORK, NY / ACCESSWIRE /...
« Older Entries

Recent Posts

  • ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Platinum Refractory/ Resistant Ovarian Cancer at SITC 2023
  • ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Solid Tumors Refractory to Standard of Care at the Immuno-oncology Summit 2023
  • ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy
  • ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer
  • ENB Therapeutics Demonstrated Early Efficacy in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab

Archives

  • November 2023
  • July 2023
  • November 2022
  • May 2022
  • February 2021
  • November 2020
  • February 2019
  • September 2018
  • April 2016
  • January 2016
  • June 2015

Categories

  • Press Releases
  • Uncategorized

Explore

  • Home
  • About
  • Pipeline
  • News/Blog
  • Contact Us

Recent Posts

Click Here

ENB Therapeutics
Alexandria Center For Life Sciences,
Launch Labs
430 E 29th Street, 14th Floor
New York, NY 10016
(212) 792-2317
info@enbpharma.com

Designed by Visual Fuel Design